Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT03719989 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma
Relapsed Non Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma

Interventions

DRUG: azacitidine plus R-GDP

Sponsor

Seoul National University Hospital